George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Any thoughts?
http://tinyurl.com/ho7fhrz David Budd, chief executive of Epistem Holdings PLC (LON:EHP) says recent tests show its rapid diagnostic system Genedrive is “as accurate as the gold standard”. Genedrive, which has already launched in India for TB, performed well in EU-funded hepatitis (HCV) study carried out by Institut Pasteur and Hopital Cochin in Paris. It was 100% accurate in detecting inherited genetic polymorphisms in Hepatitis (HCV) patients compared to the current 'gold-standard' laboratory test, Roche's TaqMan PCR. “We feel that based on the results that we’ve had today with Institut Pasteur on the qualitative side of detecting HCV that we are in a great position now to go out and find partners that will work with us on commercialising and taking that product to market,” Budd says.
http://tinyurl.com/z9crjeq David Budd, chief executive of Epistem Holdings PLC (LON:EHP) says the news it has reached a major milestone in its development with the full commercial launch of its Genedrive tuberculosis (TB) and antibiotic resistance test, is “hugely significant”. The company, a specialist in molecular diagnostics and personalised medicine, has teamed up with Xcelris Labs to start selling the product in India. Next up, Budd says, the company hopes to build up a “menu of tests” over time, now that the company has a “robust technology platform in place”.
Agree. I missed the RNS when it was issued, but a nice $2.9m funding award can't go amiss!
news folks!
...of activity with some buys coming through and a small rise in SP.
Successful assessment of Genedrive enabling clinical trials of hepatitis test in Europe with a view to launch in 2017. Good progress.
No other Investors on here?
New CEO appointed
Some Directors have been buying. Not massive amounts but respectable. Very good sign that things are ticking along nicely behind the scenes. Could bounce quite well in news IMO, so long as it's good!
Really need some news to loosen this up and provide some liquidity
Is no one else invested here?
..... Wish I was investing now rather than a few months back!
Preliminary results out.
...due out on the 28th
Trading update out. CEO leaves but nice US Govt contract award and cash position looks robust pending roll out of Genedrive in India.
....on no news as far as I can see. Any ideas what's going on?
Topped up on this set back which I regard as minor and a buying opportunity.
http://tinyurl.com/khf7khe Matthew Walls, chief executive of Epistem (Lon:EHP), says distribution of its handheld TB diagnostic device in India paves the way for other distributor-based deals globally. Walls tells Proactive Investors the test market for TB will be worth US$2bln by 2020, and the biotechnology company’s signature Genedrive tool lends itself to testing all bacterial, viral, fungal and somatic mutations of the body. Described as 'breakthrough next generation technology' Genedrive is gathering more commercial exposure and Walls says more funds may be required over the next few months to accelerate the device’s push into the global marketplace.
Nice rise this morning on the back of this RNS. Wish I had bought more!
Just bought a few of these as a bit of a punt. Looks like a good time.
my buy showing as a sell mmmm carnt trust buying/selling charts looks like 2015 1st quarter it could become interesting for this share
looks good to me , what's your thoughts shan
Successful completion of Genedrive® Indian clinical trials and regulatory submission Epistem Holdings Plc (LSE: EHP), the personalised medicine and biotechnology company, announces today the successful completion of its Genedrive® Indian clinical evaluation study and the regulatory submission with the Drug Controller General of India (DCGI) of its first test for the diagnosis of Tuberculosis and Rifampicin antibiotic resistance (TB). Epistem is now awaiting approval from the Indian regulator for a license to import and sell its first major infectious disease assay for TB, which is anticipated early in 2015.